Attached files
| file | filename |
|---|---|
| 10-K/A - FORM 10-K/A - SUNOVION CNS DEVELOPMENT CANADA ULC | v434613_10ka.htm |
| EX-31.2 - EXHIBIT 31.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v434613_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v434613_ex31-1.htm |
Exhibit 32.1
CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to Annual Report on Form 10-K/A of Cynapsus Therapeutics Inc. (the “Company”) for the year ended December 31, 2015 (the “Report”), the undersigned hereby certify in their capacities as Chief Executive Officer and Chief Financial Officer of the Company, respectively, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 18, 2016 | By: | /s/ Anthony Giovinazzo | |
| Anthony Giovinazzo | |||
| President and Chief Executive Officer | |||
| (principal executive officer) | |||
| Dated: March 18, 2016 | By: | /s/ Andrew Williams | |
| Andrew Williams | |||
| Chief Operating Officer and Chief Financial Officer | |||
| (principal financial officer) |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.